000165405 001__ 165405
000165405 005__ 20260108143203.0
000165405 0247_ $$2doi$$a10.1182/blood-2017-07-795302
000165405 0248_ $$2sideral$$a101907
000165405 037__ $$aART-2017-101907
000165405 041__ $$aeng
000165405 100__ $$aSalar, Antonio
000165405 245__ $$aLong-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
000165405 260__ $$c2017
000165405 5203_ $$aTo the editor: Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) present in most cases as localized disease and can be successfully treated with local therapies or antibiotics.1¿¿-4 Moreover, patients with multicentric or extensive disease or relapsed disease may require systemic treatment with chemotherapy and/or rituximab.5¿¿-8 Also, considering the relative frequency of late relapses9 and that extragastric MALT lymphomas have an increased relapse risk, 10 systemic treatment has also been used in the first-line setting. Several chemotherapy agents, anti-CD20 monoclonal antibodies, immunomodulatory agents, and their combinations have been demonstrated to be effective specifically in MALT lymphomas.11¿¿-14 Herewith, we report the long-term results of the MALT 2008-01 phase 2 trial15 using a response-adapted protocol with the combination of rituximab and bendamustine (RB) as first-line treatment of MALT lymphomas after a median follow-up of 7 years. This trial was registered at www.clinicaltrials.gov as #NCT01015248 and in EudraCT as #2008-007725-39....
000165405 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000165405 590__ $$a15.132$$b2017
000165405 591__ $$aHEMATOLOGY$$b2 / 71 = 0.028$$c2017$$dQ1$$eT1
000165405 592__ $$a6.434$$b2017
000165405 593__ $$aBiochemistry$$c2017$$dQ1
000165405 593__ $$aImmunology$$c2017$$dQ1
000165405 593__ $$aHematology$$c2017$$dQ1
000165405 593__ $$aCell Biology$$c2017$$dQ1
000165405 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/publishedVersion
000165405 700__ $$aDomingo-Domenech, Eva
000165405 700__ $$aPanizo, Carlos
000165405 700__ $$aNicolás, Concepción
000165405 700__ $$aBargay, Joan
000165405 700__ $$aMuntañola, Ana
000165405 700__ $$aCanales, Miguel
000165405 700__ $$aBello, José Luis
000165405 700__ $$aSancho, Juan Manuel
000165405 700__ $$aTomás, José Francisco
000165405 700__ $$aRodríguez, María José
000165405 700__ $$aPeñalver, Javier
000165405 700__ $$aGrande, Carlos
000165405 700__ $$aSánchez-Blanco, José Javier
000165405 700__ $$0(orcid)0000-0001-8515-3599$$aPalomera, Luis$$uUniversidad de Zaragoza
000165405 700__ $$aArranz, Reyes
000165405 700__ $$aConde, Eulogio
000165405 700__ $$0(orcid)0000-0003-2078-8205$$aGarcía, Mar
000165405 700__ $$aGarcía, Juan Fernando
000165405 700__ $$aCaballero, Dolores
000165405 700__ $$aMontalbán, Carlos
000165405 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000165405 773__ $$g130, 15 (2017), 1772-1774$$pBlood$$tBlood$$x0006-4971
000165405 8564_ $$s579491$$uhttps://zaguan.unizar.es/record/165405/files/texto_completo.pdf$$yVersión publicada
000165405 8564_ $$s3670375$$uhttps://zaguan.unizar.es/record/165405/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165405 909CO $$ooai:zaguan.unizar.es:165405$$particulos$$pdriver
000165405 951__ $$a2026-01-08-14:09:58
000165405 980__ $$aARTICLE